William Blair Estimates Evommune’s Q3 Earnings (NYSE:EVMN)

Evommune, Inc. (NYSE:EVMN) – Equities research analysts at William Blair issued their Q3 2025 EPS estimates for Evommune in a note issued to investors on Monday, December 1st. William Blair analyst M. Phipps expects that the company will post earnings of ($12.16) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Evommune’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.32) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($3.89) EPS.

A number of other analysts also recently commented on EVMN. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a report on Monday. Evercore ISI initiated coverage on Evommune in a research note on Monday. They set an “outperform” rating and a $40.00 price target for the company. Leerink Partners initiated coverage on Evommune in a research note on Monday. They issued an “outperform” rating and a $42.00 price objective on the stock. Wall Street Zen upgraded Evommune to a “hold” rating in a report on Thursday, November 20th. Finally, Cantor Fitzgerald started coverage on shares of Evommune in a report on Monday. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $39.33.

Evommune Stock Up 0.8%

Shares of EVMN opened at $21.22 on Wednesday. Evommune has a fifty-two week low of $16.70 and a fifty-two week high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.